Etanercept improves the health-related quality of life of patients with psoriasis: Results of a phase III randomized clinical trial - 21/08/11
![](/templates/common/images/mail.png)
![](/templates/common/images/entites/lowast.gif)
Winston Salem, North Carolina; Boston, Massachusetts; Salt Lake City, Utah; and Thousand Oaks, California
Abstract |
In this randomized, double-blind, phase III trial, patients with psoriasis received etanercept for 24 weeks or placebo for 12 weeks followed by etanercept for 12 weeks. At week 12, improvement in Dermatology Life Quality Index was 47% to 61% with etanercept compared with 11% with placebo (P < .0001). Etanercept rapidly and substantially improved patients’ health-related quality of life.
Le texte complet de cet article est disponible en PDF.Plan
Funding sources: Amgen Inc and its subsidiaries. Disclosure: Dr Feldman has received consulting, research, and speaking support from Amgen. Dr Kimball has served as consultant and received honoraria for speaking from Amgen and was supported for participating in this study along with other research studies supported by Amgen. Dr Krueger acted as the principal investigator for the portion of this trial that was conducted at the University of Utah. During the past 5 years he has not served on the Amgen Board of Advisors for etanercept, but has acted on an ad hoc basis as an advisor and is an Amgen-sponsored speaker. He does not own stock or have other equity ownership, stock options, patent licensing arrangements, or payments for conducting or publicizing the study. He has similar positions for companies with competing products. Drs Woolley and Jahreis are employees of Amgen Inc. Dr Lalla is a former employee of Amgen Inc. Previously presented in abstract and poster forms only at the American Academy of Dermatology Summer Academy Meeting, July 25, 2003, Chicago, IL; the American Academy of Dermatology Annual Meeting, February 6, 2004, Washington, DC; and the Society for Investigative Dermatology Meeting, April 24, 2004, Providence, RI. |
Vol 53 - N° 5
P. 887-889 - novembre 2005 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?